Khiron Life Sciences Corp. (OTCQX: KHRNF) (TSXV:KHRN) (Frankfurt:A2JMZC), announced its market entry into Switzerland with initial sales of new products and increases its product offerings in Germany and UK.

In August 2022, Khiron completed the acquisition of its EU GMP-certified manufacturer and wholesaler, Pharmadrug GmbH in Germany. Since then, the company has obtained import and export permits across Germany and the UK bringing to market its new product offerings, as well as looking for opportunities to expand its presence in other European markets.

The Alpine Republic of Switzerland has become the next market for Khiron, with Khiron's established reputation in Germany helping to pave the way. …

Full story available on Benzinga.com